Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 365

1.

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Watson GS, Craft S.

CNS Drugs. 2003;17(1):27-45. Review.

PMID:
12467491
[PubMed - indexed for MEDLINE]
2.

Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis.

Watson GS, Craft S.

J Neurol Sci. 2006 Jun 15;245(1-2):21-33. Epub 2006 Apr 24. Review.

PMID:
16631207
[PubMed - indexed for MEDLINE]
3.

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

Craft S.

Curr Alzheimer Res. 2007 Apr;4(2):147-52. Review.

PMID:
17430239
[PubMed - indexed for MEDLINE]
4.

Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?

Biessels GJ, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1041-4. Review.

PMID:
16246041
[PubMed - indexed for MEDLINE]
5.

Links between Alzheimer's disease and diabetes.

Sun MK, Alkon DL.

Drugs Today (Barc). 2006 Jul;42(7):481-9. Review.

PMID:
16894402
[PubMed - indexed for MEDLINE]
6.

Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease.

Watson GS, Craft S.

Eur J Pharmacol. 2004 Apr 19;490(1-3):97-113. Review.

PMID:
15094077
[PubMed - indexed for MEDLINE]
7.

Impaired insulin signaling and the pathogenesis of Alzheimer's disease.

Revill P, Moral MA, Prous JR.

Drugs Today (Barc). 2006 Dec;42(12):785-90. Review.

PMID:
17285151
[PubMed - indexed for MEDLINE]
8.

Insulin resistance and Alzheimer's disease: molecular links & clinical implications.

Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB.

Curr Alzheimer Res. 2008 Oct;5(5):438-47.

PMID:
18855585
[PubMed - indexed for MEDLINE]
9.

The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.

Blass JP, Gibson GE.

Rev Neurol (Paris). 1991;147(6-7):513-25. Review.

PMID:
1962057
[PubMed - indexed for MEDLINE]
10.

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S.

Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8.

PMID:
16286438
[PubMed - indexed for MEDLINE]
11.

Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.

Vázquez M, Silvestre JS, Prous JR.

Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):515-23. Review.

PMID:
12500431
[PubMed - indexed for MEDLINE]
12.

Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation.

Craft S.

Neurobiol Aging. 2005 Dec;26 Suppl 1:65-9. Epub 2005 Nov 2. Review.

PMID:
16266773
[PubMed - indexed for MEDLINE]
13.

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Diamant M, Heine RJ.

Drugs. 2003;63(13):1373-405. Review.

PMID:
12825962
[PubMed - indexed for MEDLINE]
14.

Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.

Walter H, Lübben G.

Drugs. 2005;65(1):1-13. Review.

PMID:
15610048
[PubMed - indexed for MEDLINE]
15.

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.

Zhao WQ, Townsend M.

Biochim Biophys Acta. 2009 May;1792(5):482-96. doi: 10.1016/j.bbadis.2008.10.014. Epub 2008 Nov 5. Review.

PMID:
19026743
[PubMed - indexed for MEDLINE]
Free Article
16.

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R.

J Mol Neurosci. 2003;20(3):349-56. Review.

PMID:
14501019
[PubMed - indexed for MEDLINE]
17.

Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.

Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC.

Am J Cardiovasc Drugs. 2006;6(4):231-42. Review.

PMID:
16913824
[PubMed - indexed for MEDLINE]
18.

Links between Alzheimer's disease and diabetes.

Sun MK, Alkon DL.

Timely Top Med Cardiovasc Dis. 2006 Oct 1;10:E24.

PMID:
17066144
[PubMed]
Free Article
19.

Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.

Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E.

J Neurosci. 2008 Sep 10;28(37):9287-96. doi: 10.1523/JNEUROSCI.3348-08.2008.

PMID:
18784309
[PubMed - indexed for MEDLINE]
Free Article
20.

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.

de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR.

J Alzheimers Dis. 2006 Sep;10(1):89-109. Review.

PMID:
16988486
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk